Literature DB >> 17502722

Chronic renal failure among HIV-1-infected patients.

Amanda Mocroft1, Ole Kirk, Jose Gatell, Peter Reiss, Panagiotis Gargalianos, Kai Zilmer, Marek Beniowski, Jean-Paul Viard, Schlomo Staszewski, Jens D Lundgren.   

Abstract

BACKGROUND: The role of exposure to antiretrovirals in chronic renal failure (CRF) is not well understood. Glomerular filtration rates (GFR) are estimated using the Cockcroft-Gault (CG) or Modification of Diet in Renal Disease (MDRD) equations.
METHODS: Baseline was arbitrarily defined as the first recorded GFR; patients with two consecutive GFR < or = 60 ml/min per 1.73 m(2) were defined as having CRF. Logistic regression was used to determine odds ratio (OR) of CRF at baseline. ART exposure (yes/no or cumulative exposure) prior to baseline was included in multivariate models (adjusted for region of Europe, age, prior AIDS, CD4 cell count nadir, viral load, hypertension and use of nephrotoxic anti-infective therapy).
RESULTS: Using CG, the median GFR at baseline (n = 4474) was 94.4 (interquartile range, 80.5-109.3); 158 patients (3.5%) had CRF. Patients with CRF were older (median, 61.9 versus 43.1 years), had lower CD4 cell count nadirs (median, 80 versus 137 cells/microl), and were more likely to be diagnosed with AIDS (44.3 versus 30.4%), diabetes (16.5 versus 4.3%) or hypertension (53.8 versus 26.4%), all P < 0.001. In a multivariate model any use of indinavir [odds ratio (OR) 2.49; 95% confidence interval (CI), 1.62-3.83] or tenofovir (OR, 2.18; 95% CI, 1.25-3.81) was associated with increased odds of CRF, as was cumulative exposure to indinavir (OR, 1.15 per year of exposure; 95% CI, 1.06-1.25) or tenofovir (OR, 1.60; 95% CI, 1.20-2.15). Highly consistent results were seen using the MDRD formula.
CONCLUSIONS: Among antiretrovirals, only exposure to indinavir or tenofovir was associated with increased odds of CRF. We used a confirmed low GFR to define CRF to increase the robustness of our analysis, although there are several potential biases associated with this cross-sectional analysis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17502722     DOI: 10.1097/QAD.0b013e3280f774ee

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  73 in total

Review 1.  An Increase in Serum Creatinine after Initiation of Fenofibrate in an HIV-Infected Individual: A Case Report and Review of the Literature.

Authors:  Christine B Bruno; Jeffrey M Schapiro; Parya Saberi
Journal:  J Int Assoc Physicians AIDS Care (Chic)       Date:  2011-04-25

2.  Role of CD8 T Cell Replicative Senescence in Human Aging and in HIV-mediated Immunosenescence.

Authors:  Jeffrey N Dock; Rita B Effros
Journal:  Aging Dis       Date:  2011-10       Impact factor: 6.745

3.  Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy.

Authors:  E T Overton; D Nurutdinova; J Freeman; W Seyfried; K E Mondy
Journal:  HIV Med       Date:  2009-03-11       Impact factor: 3.180

4.  Risk factors for kidney disease among HIV-1 positive persons in the methadone program.

Authors:  Bartłomiej Matłosz; Ewa Pietraszkiewicz; Ewa Firląg-Burkacka; Ewa Grycner; Andrzej Horban; Justyna D Kowalska
Journal:  Clin Exp Nephrol       Date:  2018-09-14       Impact factor: 2.801

Review 5.  The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis.

Authors:  Christina M Wyatt; Carlos Malvestutto; Steven G Coca; Paul E Klotman; Chirag R Parikh
Journal:  AIDS       Date:  2008-09-12       Impact factor: 4.177

6.  Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapy.

Authors:  Babafemi Taiwo; Elizabeth L Yanik; Sonia Napravnik; Patrick Ryscavage; Susan L Koletar; Richard Moore; W Christopher Mathews; Heidi M Crane; Kenneth Mayer; Anne Zinski; James S Kahn; Joseph J Eron
Journal:  AIDS       Date:  2013-06-19       Impact factor: 4.177

Review 7.  HIV and kidney disease in sub-Saharan Africa.

Authors:  June Fabian; Saraladevi Naicker
Journal:  Nat Rev Nephrol       Date:  2009-10       Impact factor: 28.314

8.  The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy.

Authors:  Christina M Wyatt; Susan Morgello; Rebecca Katz-Malamed; Catherine Wei; Mary E Klotman; Paul E Klotman; Vivette D D'Agati
Journal:  Kidney Int       Date:  2008-12-03       Impact factor: 10.612

9.  Prevalence of renal disease within an urban HIV-infected cohort in northern Italy.

Authors:  Leonardo Calza; Elisa Vanino; Eleonora Magistrelli; Caterina Salvadori; Alessandra Cascavilla; Vincenzo Colangeli; Maria Assunta Di Bari; Roberto Manfredi; Pierluigi Viale
Journal:  Clin Exp Nephrol       Date:  2013-05-28       Impact factor: 2.801

10.  Renal impairment in a rural African antiretroviral programme.

Authors:  Cara Franey; Deborah Knott; Till Barnighausen; Martin Dedicoat; Ahmed Adam; Richard J Lessells; Marie-Louise Newell; Graham S Cooke
Journal:  BMC Infect Dis       Date:  2009-08-28       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.